Lilly’s Tirzepatide Effective, But Tolerability Still A Limitation
Drug Reduces A1C, Weight In Diabetes
Executive Summary
Tirzepatide’s efficacy seems to outweigh tolerability concerns at the lower doses, but the highest dose may be relegated to niche use.
You may also be interested in...
Lilly's Tirzepatide Hits On Phase III, But Poised To Face A Crowded Diabetes Market
Starting patients on a low dose yielded lower rates of GI adverse events for the GIP/GLP-1 agonist, but it remains uncertain how differentiated tirzepatide will be against entrenched GLP-1 rivals.
Questions Persist On Lilly’s Tirzepatide And Tolerability
Concerns about gastrointestinal tolerability continue to weigh on Lilly’s tirzepatide, despite improvements seen in a Phase II dose-escalation study. Lilly believes the adverse events are manageable.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports